TNFRSF4 and cancer: We anticipate that 89Zr-ivuxolimab may be instrumental in identifying patients with cancer whose tumors have high basal OX40 expression, pinpointing those patients who are most likely to benefit from OX40 agonist therapy, either alone or in combination with immune-checkpoint inhibitors (27).